文献速递妇科

卵巢癌患者PARP抑制剂总费用与自付费用分析

Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
PubMed 文献 · Gynecol Oncol · 2020-12-27

本研究基于MarketScan(2014-2017)和SEER-Medicare(2014-2016)数据库,识别接受尼拉帕利、奥拉帕利或芦卡帕利处方的卵巢癌患者,估算30天供应量的药物费用。结果显示商业保险受益者中位总费用为13,342美元,自付费用中位44美元;SEER-Medicare受益者中位总费用12,798美元,自付费用中位370美元,且PARP抑制剂占患者自付药物支出的中位90.8%和99.0%。

要点

  • 商业保险患者PARP抑制剂中位总费用13,342美元,自付中位44美元。
  • SEER-Medicare患者自付中位370美元,高于商业保险患者。
  • 补充医疗补助处方覆盖可降低双资格患者自付费用。

核心结论

  • 尽管保险公司承担PARP抑制剂大部分费用,但自付费用仍占患者药物支出的多数。
  • SEER-Medicare受益者自付费用高于商业保险患者,补充医疗补助处方覆盖可抵消这一差异。

研究设计与样本

  • 回顾性队列研究,数据来自MarketScan(2014-2017)和SEER-Medicare(2014-2016)数据库。
  • 共纳入590名商业保险受益者和213名SEER-Medicare受益者,中位处方持续时间112天。
  • 药物费用按30天供应量估算,采用描述性统计和Wilcoxon秩和检验。

主要发现

  • 商业保险受益者中位总费用13,342美元(IQR 12,022-14,256),自付中位44美元(IQR 0-120)。
  • 商业保险受益者中PARP抑制剂占自付药物支出中位90.8%。
  • 高免赔额健康计划与自付费用升高无关(N=570;中位0美元 vs 45美元,P=0.87)。
  • SEER-Medicare受益者中位总费用12,798美元(IQR 11,704-13,180),自付中位370美元(IQR 2-1234)。
  • SEER-Medicare受益者中PARP抑制剂占自付药物支出中位99.0%;双资格患者自付中位1美元 vs 911美元(N=209,P<0.001)。

临床怎么用

  • 处方PARP抑制剂时应评估患者保险类型及自付费用负担。
  • 对SEER-Medicare受益者可关注补充医疗补助处方覆盖以降低自付费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate total and out-of-pocket costs for poly(ADP-ribose) polymerase (PARP) inhibitors and differences based on insurance characteristics. METHODS: We identified ovarian cancer patients who were prescribed niraparib, olaparib, or rucaparib from the MarketScan (2014-2017) and Surveillance, Epidemiology, and End Results (SEER)-Medicare (2014-2016) databases. Drug costs were estimated for a 30-day supply. Descriptive statistics and Wilcoxon rank sum tests were performed. RESULTS: 590 commercially insured beneficiaries from MarketScan and 213 SEER-Medicare beneficiaries were prescribed PARP inhibitors for a median 112 days. For commercially insured beneficiaries, median total cost was $13,342 (IQR $12,022-$14,256). Median out-of-pocket cost was $44 (IQR $0-$120) and PARP inhibitors accounted for a median 90.8% of patients' total out-of-pocket drug spending. High-deductible health plan was not associated with higher out-of-pocket costs (N = 570; median $0 vs. $45, P = 0.87). For SEER-Medicare beneficiaries, median total cost was $12,798 (IQR $11,704-$13,180). Median out-of-pocket cost was $370 (IQR $2-$1234) and PARP inhibitors accounted for a median 99.0% of patients' total out-of-pocket drug spending. Out-of-pocket costs were lower for dual-eligible patients with supplemental Medicaid prescription coverage (N = 209; median $1 vs. $911, P < 0.001). CONCLUSIONS: Although insurers are responsible for a large proportion of PARP inhibitor costs, out-of-pocket costs for PARP inhibitors account for a majority of patients' drug spending. SEER-Medicare beneficiaries had higher out-of-pocket costs than patients with commercial insurance, which was offset for those with supplemental Medicaid prescription coverage.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Liang MI, Chen L, Hershman DL, et al. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. Gynecol Oncol. 2020. PMID: 33375989. doi:10.1016/j.ygyno.2020.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。